What does AEMD's Q4 forecast reveal about future earnings?

**AEMD's Q4 forecast indicates a challenging financial outlook for the company**. The estimated EPS and revenue for the fiscal quarter ending in Q4 2025 are not available, which suggests that analysts are unable to provide a financial forecast for this period. This could be due to the lack of available data or the company's uncertain financial position.

1. **Current Financial Performance**: AEMD reported a quarterly adjusted loss of 13 cents per share for the quarter ended December 31, 2024, which is higher than the same quarter last year's EPS of -$1.37. The company's reported EPS for the quarter was a loss of 13 cents, and the quarterly loss was $1.75 million.
2. **Analyst Expectations**: Wall Street expected a loss of 23 cents to -20 cents per share for the quarter, with a mean expectation of a loss of 21 cents per share. The lack of available data for Q4 2025 makes it impossible to provide a comparison with these expectations.
3. **Stock Performance and Market Sentiment**: AEMD's shares had fallen by 20.7% this quarter, and the company is trading at approximately two times its cash value. This decline in stock price and the company's financial losses indicate a challenging market environment for AEMD.
4. **Strategic Focus and Future Outlook**: AEMD is focusing on oncology trials in Australia and India and has reported a cash balance of $4.8 million at the end of December 2024, with no debt. The company aims to raise additional funds to support ongoing clinical trials, which suggests a need for further capital to counterbalance cash burn.

In conclusion, AEMD's Q4 forecast reflects a company facing significant financial challenges, with ongoing losses and uncertain revenue prospects. The lack of available data for Q4 2025 makes it difficult to provide a precise forecast of future earnings, but the trend of declining EPS and increasing losses suggests that AEMD is navigating a difficult period in its financial history.